Carboxymethylated pyridoindole antioxidants as aldose reductase inhibitors: Synthesis, activity, partitioning, and molecular modeling.

Starting from the efficient hexahydropyridoindole antioxidant stobadine, a series of carboxymethylated tetrahydro- and hexahydropyridoindole derivatives was synthesized and tested for the inhibition of aldose reductase, an enzyme involved in the etiology of diabetic complications. In vitro inhibiton of rat lens aldose reductase was determined by a conventional method. Kinetic analysis of (2-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-yl)-acetic acid (5b) and (2-phenethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-yl)-acetic acid (5c), the most potent compounds in this series with activities in micromolar range, showed uncompetitive inhibition. In addition to the importance of the acidic function, the inhibition efficacy was highly influenced by the steric conformation of the lipophilic aromatic backbone when comparing tetrahydro- and hexahydropyridoindole congeners. Selectivity with respect to the closely related aldehyde reductase was determined by measuring the corresponding inhibitory activities. Antioxidant action of the novel compounds was documented in a DPPH test and in a liposomal membrane model, oxidatively stressed by peroxyl radicals. The presence of a basicity center at the tertiary nitrogen, in addition to the acidic carboxylic function, predisposes these compounds to form double charged zwitterionic species, a characteristic which may remarkably affect their pH-lipophilicity profile. For compounds 5b and 5c, a maximal distribution ratio in a system comprised of 1-octanol/phosphate buffer was recorded near the neutral physiological pH, the region where the isoelectric point lies. Molecular docking simulations into the ALR2 active site performed for the zwitterionic species provided an explanation for the observed structure-activity relationships and the calculated parameters were in agreement with characteristic differences in the stereoelectronic profiles of the tetrahydro- versus hexahydropyridoindoles. 'Drug-likeness' of the novel aldose reductase inhibitors was assessed by applying the criteria of Lipinski's 'rule of five'.

[1]  V. Demopoulos,et al.  Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides. , 2003, Journal of Medicinal Chemistry.

[2]  K. Bohren,et al.  Mechanism of human aldehyde reductase: characterization of the active site pocket. , 1995, Biochemistry.

[3]  O. El-Kabbani,et al.  Modelling studies of the active site of human sorbitol dehydrogenase: an approach to structure-based inhibitor design of the enzyme. , 2001, Bioorganic & medicinal chemistry letters.

[4]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[5]  S. Stolc,et al.  Antioxidant and pharmacodynamic effects of pyridoindole stobadine. , 1998, General pharmacology.

[6]  J. Sangster.  Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry , 1997 .

[7]  S. Bessman,et al.  Protein determination by Lowry's method in the presence of sulfhydryl reagents. , 1972, Analytical biochemistry.

[8]  G. Klopman,et al.  A new proposed model of aldose reductase enzyme inhibition on the basis of an artificial intelligence approach: A computer automated structure evaluation (case) study , 1991 .

[9]  S. Hayman,et al.  ISOLATION AND PROPERTIES OF LENS ALDOSE REDUCTASE. , 1965, The Journal of biological chemistry.

[10]  Milan Stefek,et al.  Free radical scavenging and antioxidant activities of substituted hexahydropyridoindoles. Quantitative structure-activity relationships. , 2006, Journal of medicinal chemistry.

[11]  Z. Trnkova,et al.  Oxidative modification of serum albumin in an experimental glycation model of diabetes mellitus in vitro: effect of the pyridoindole antioxidant stobadine. , 1999, Life sciences.

[12]  S. Stolc,et al.  Pentose Phosphate Pathway, Glutathione-Dependent Enzymes and Antioxidant Defense During Oxidative Stress in Diabetic Rodent Brain and Peripheral Organs: Effects of Stobadine and Vitamin E , 2003, Neurochemical Research.

[13]  S. Stolc,et al.  In vivo treatment with stobadine prevents lipid peroxidation, protein glycation and calcium overload but does not ameliorate Ca2+ -ATPase activity in heart and liver of streptozotocin-diabetic rats: comparison with vitamin E. , 2002, Biochimica et biophysica acta.

[14]  H. Sies,et al.  Antioxidant activity of the pyridoindole stobadine. Pulse radiolytic characterization of one-electron-oxidized stobadine and quenching of singlet molecular oxygen. , 1992, Chemical research in toxicology.

[15]  P. Oates.  Polyol pathway and diabetic peripheral neuropathy. , 2002, International review of neurobiology.

[16]  G. Rastelli,et al.  Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches , 1999, Medicinal research reviews.

[17]  M. Remko,et al.  Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. , 2006, Bioorganic & medicinal chemistry.

[18]  O. El-Kabbani,et al.  Modelling studies on the binding of substrate and inhibitor to the active site of human sorbitol dehydrogenase. , 2000, Bioorganic & medicinal chemistry letters.

[19]  D. D. Perrin,et al.  Purification of laboratory chemicals , 1966 .

[20]  Aruni Bhatnagar,et al.  Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. , 2005, Endocrine reviews.

[21]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[22]  Z. Chen,et al.  Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. , 1998, Bioorganic & medicinal chemistry.

[23]  O. El-Kabbani,et al.  Aldose reductase structures: implications for mechanism and inhibition , 2004, Cellular and Molecular Life Sciences CMLS.

[24]  G. Rastelli,et al.  Pharmacological approaches to the treatment of diabetic complications , 2000 .

[25]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[26]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[27]  L. Beneš,et al.  Inhibition of cumene hydroperoxide-induced lipid peroxidation by a novel pyridoindole antioxidant in rat liver microsomes. , 1992, Pharmacology & toxicology.

[28]  E. Novellino,et al.  Spirohydantoin derivatives of thiopyrano[2,3-b]pyridin-4(4H)-one as potent in vitro and in vivo aldose reductase inhibitors. , 2005, Bioorganic & medicinal chemistry.

[29]  J. Dřímal,et al.  The pyridoindole antioxidant stobadine attenuates albuminuria, enzymuria, kidney lipid peroxidation and matrix collagen cross-linking in streptozotocin-induced diabetic rats. , 2002, Methods and findings in experimental and clinical pharmacology.

[30]  B. Mihaljević,et al.  The reevaluation of the ferric thiocyanate assay for lipid hydroperoxides with special considerations of the mechanistic aspects of the response. , 1996, Free radical biology & medicine.

[31]  A. Ceylan,et al.  Reactive oxygen species mediate abnormal contractile response to sympathetic nerve stimulation and noradrenaline in the vas deferens of chronically diabetic rats: effects of in vivo treatment with antioxidants , 2005, Fundamental & clinical pharmacology.

[32]  T. Tomizaki,et al.  Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors , 2004, Proteins.

[33]  E. Novellino,et al.  Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity. , 2007, Journal of medicinal chemistry.

[34]  Shuichi Miyamoto,et al.  Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications , 2002 .

[35]  M. S. Blois,et al.  Antioxidant Determinations by the Use of a Stable Free Radical , 1958, Nature.

[36]  J. Boire,et al.  Synthesis of pyridazine acetic acid derivatives possessing aldose reductase inhibitory activity and antioxidant properties , 1994 .

[37]  L. Benet,et al.  Potentiometric determination of dissociation constants. , 1967, Journal of pharmaceutical sciences.

[38]  L. Račková,et al.  Structural aspects of antioxidant activity of substituted pyridoindoles , 2002, Redox report : communications in free radical research.

[39]  Z. Kyselova,et al.  Effect of the pyridoindole antioxidant stobadine on development of experimental diabetic cataract and on lens protein oxidation in rats: comparison with vitamin E and BHT. , 2005, Molecular vision.

[40]  J. Deruiter,et al.  Inhibitory activity and mechanism of inhibition of the N-[[(4-benzoylamino)phenyl]sulfonyl]amino acid aldose reductase inhibitors. , 1990, Biochemical pharmacology.

[41]  Alex Avdeef,et al.  Potentiometric pKa determination of water-insoluble compounds: validation study in methanol/water mixtures , 1997 .

[42]  Ioannis Nicolaou,et al.  [1-(3,5-difluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone as a bioisostere of a carboxylic acid aldose reductase inhibitor. , 2004, Journal of medicinal chemistry.

[43]  N. Sharpless,et al.  Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. , 1985, Journal of medicinal chemistry.

[44]  J. Deruiter,et al.  N- and 2-substituted N-(phenylsulfonyl)glycines as inhibitors of rat lens aldose reductase. , 1989, Journal of medicinal chemistry.

[45]  F. Yülek,et al.  Effects of stobadine and vitamin E in diabetes-induced retinal abnormalities: involvement of oxidative stress. , 2007, Archives of medical research.

[46]  O. El-Kabbani,et al.  Aldehyde reductase: the role of C-terminal residues in defining substrate and cofactor specificities. , 1998, Archives of biochemistry and biophysics.

[47]  H. Haraguchi,et al.  A flavone from Manilkara indica as a specific inhibitor against aldose reductase in vitro. , 2003, Planta medica.

[48]  G. Rastelli,et al.  1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. , 1999, Journal of medicinal chemistry.

[49]  O. El-Kabbani,et al.  Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites , 2007, Cellular and Molecular Life Sciences.

[50]  C. Yabe-Nishimura,et al.  Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. , 1998, Pharmacological reviews.

[51]  N. Tribulova,et al.  Effect of dietary supplementation with the pyridoindole antioxidant stobadine on antioxidant state and ultrastructure of diabetic rat myocardium , 2000, Acta Diabetologica.

[52]  B. Matuszczak,et al.  On the Synthesis of Bioisosters of O‐Benzothiazolyloxybenzoic Acids and Evaluation as Aldose Reductase Inhibitors , 2005, Archiv der Pharmazie.

[53]  I. Obrosova.  Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. , 2005, Antioxidants & redox signaling.

[54]  R. Bates,et al.  Determination of pH;: Theory and practice , 1964 .

[55]  Connie Darmanin,et al.  Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. , 2005, Journal of medicinal chemistry.

[56]  Bernard Testa,et al.  Lipophilicity Profiles of Ampholytes. , 1997, Chemical reviews.

[57]  M. Lou,et al.  Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats. , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.